Law Simon, Derry Sheena, Moore R Andrew
Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU.
Cochrane Database Syst Rev. 2010 Apr 14(4):CD008042. doi: 10.1002/14651858.CD008042.pub2.
BACKGROUND: Cluster headache is an uncommon, but severely painful and disabling condition, with rapid onset. Validated treatment options are limited, and first-line therapy includes inhaled oxygen. Alternative therapies such as intranasal lignocaine and ergotamine are not as commonly used and are less well studied. Triptans are successfully used to treat migraine attacks and, because of this, they may also be useful for cluster headache. OBJECTIVES: To determine the efficacy and tolerability of triptans for the acute treatment of cluster headaches. SEARCH STRATEGY: We searched Cochrane CENTRAL, MEDLINE and EMBASE for studies through 22 January 2010. SELECTION CRITERIA: Randomised, double-blind, placebo-controlled studies of triptans for acute treatment of cluster headache episodes. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study quality and extracted data. Numbers of participants with different levels of pain relief, requiring rescue medication and experiencing adverse events and headache-associated symptoms in treatment and control groups were used to calculate relative risk and numbers needed to treat (NNT) and harm (NNH). MAIN RESULTS: All six included studies used a single dose of triptan to treat an attack of moderate to severe pain intensity. In total 231 participants received zolmitriptan 5 mg, 223 received zolmitriptan 10 mg, 131 received sumatriptan 6 mg, 88 received sumatriptan 12 mg, and 326 received placebo. Zolmitriptan was administered either orally or intranasally, and sumatriptan either subcutaneously or intranasally.Overall, the triptans studied were better than placebo for headache relief and pain-free responses, with an NNT of 2.4 for 15 minute pain relief with subcutaneous sumatriptan 6 mg (75% with sumatriptan and 32% with placebo), and 2.8 for 30 minute pain relief with intranasal zolmitriptan 10 mg (62% with zolmitriptan and 26% with placebo). Fewer participants need rescue medication with triptan than with placebo, but more experienced adverse events. AUTHORS' CONCLUSIONS: Zolmitriptan and sumatriptan are effective in the acute treatment of cluster headaches and may provide a useful treatment option, potentially offering convenience over oxygen therapy and a better safety and tolerability profile than ergotamine. Non-oral routes of administration are likely to provide better and more rapid responses.
背景:丛集性头痛虽不常见,但疼痛剧烈且使人丧失能力,起病迅速。经过验证的治疗选择有限,一线治疗包括吸入氧气。鼻内利多卡因和麦角胺等替代疗法使用不太普遍,研究也较少。曲坦类药物成功用于治疗偏头痛发作,因此它们可能对丛集性头痛也有用。 目的:确定曲坦类药物急性治疗丛集性头痛的疗效和耐受性。 检索策略:我们检索了Cochrane中心对照试验注册库、医学期刊数据库和荷兰医学文摘数据库,检索截至2010年1月22日的研究。 选择标准:曲坦类药物急性治疗丛集性头痛发作的随机、双盲、安慰剂对照研究。 数据收集与分析:两位综述作者独立评估研究质量并提取数据。使用治疗组和对照组中不同疼痛缓解水平、需要急救药物以及经历不良事件和头痛相关症状的参与者人数来计算相对风险、治疗所需人数(NNT)和伤害所需人数(NNH)。 主要结果:所有六项纳入研究均使用单剂量曲坦类药物治疗中度至重度疼痛发作。共有231名参与者接受了5毫克佐米曲坦,223名接受了10毫克佐米曲坦,131名接受了6毫克舒马曲坦,88名接受了12毫克舒马曲坦,326名接受了安慰剂。佐米曲坦通过口服或鼻内给药,舒马曲坦通过皮下或鼻内给药。总体而言,所研究的曲坦类药物在缓解头痛和达到无痛反应方面优于安慰剂,皮下注射6毫克舒马曲坦15分钟缓解疼痛的NNT为2.4(舒马曲坦组为75%,安慰剂组为32%),鼻内给予10毫克佐米曲坦30分钟缓解疼痛的NNT为2.8(佐米曲坦组为62%,安慰剂组为26%)。与安慰剂相比,使用曲坦类药物需要急救药物的参与者更少,但经历不良事件的更多。 作者结论:佐米曲坦和舒马曲坦在急性治疗丛集性头痛方面有效,可能提供一种有用的治疗选择,与氧气疗法相比可能更方便,并且比麦角胺具有更好的安全性和耐受性。非口服给药途径可能会提供更好、更快速的反应。
Cochrane Database Syst Rev. 2010-4-14
Cochrane Database Syst Rev. 2013-7-17
Cochrane Database Syst Rev. 2016-4-20
Cochrane Database Syst Rev. 2012-2-15
Cochrane Database Syst Rev. 2012-2-15
Cochrane Database Syst Rev. 2012-2-15
Cochrane Database Syst Rev. 2012-2-15
Cochrane Database Syst Rev. 2016-4-19
Cochrane Database Syst Rev. 2010-11-10
Cochrane Database Syst Rev. 2012-2-15
J Ayurveda Integr Med. 2024
Cureus. 2024-9-28
Pharmaceuticals (Basel). 2024-6-27
F1000Res. 2018-3-20
Cochrane Database Syst Rev. 2013-7-17
CNS Drugs. 2012-7-1
J Headache Pain. 2012-5
Curr Pain Headache Rep. 2012-4
Patient Prefer Adherence. 2012
Curr Pain Headache Rep. 2009-4
Cochrane Database Syst Rev. 2008-7-16
Neurology. 2005-2-8
Cephalalgia. 2004
Expert Opin Drug Saf. 2003-3